focus -WSS

focus

author：knowledge 2025-09-30 23:11:15 - browse：929

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： White House Covid adviser calls on docs to combat misinformation

focus

WSS

The unintended consequences of overturning Roe v. Wade

First transplant of an entire human eye performed

Chamber of Commerce, DOJ clash in court over drug prices

FDA weighs limits of animal data in assessing artificial wombs

Experimental asthma app from Apple and Anthem shows promise

Eli Lilly CEO gives to Mike Pence presidential super PAC

leisure time

focus

explore

Malaria cases in Florida and Texas: Here’s what you need to know

Chamber of Commerce, DOJ clash in court over drug prices

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Medicare to pay more for cardiac rehab in hospital outpatient clinics

At least 13 dead in Texas as scorching temps continue

What health policies could hitch a ride on a spending bill?

The high cost of giving birth even with insurance

Senate bill would ban some hospital facility fees

Continuity nursing helped my family in our darkest PICU moments

After decades in use, heart stents finally beat placebo

focus

CVS, Rite Aid closures threaten to worsen pharmacy deserts

FDA panel to weigh safety of artificial wombs for preterm births

Study suggests Covid rebound is far more common with Paxlovid than without

Cancer diagnosis changes perspective doctor, former hospital CEO

Covid’s new normal has set in amid another rise in cases

Senate bill would ban some hospital facility fees

Wikipedia

focus

focus

knowledge